tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Virax Biolabs initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Virax Biolabs (VRAX) with a Buy rating and $3 price target Virax is a UK-based development-stage in vitro diagnostics company focused on T cell diagnostics, the analyst tells investors in a research note. The firm says that in the U.S., Virax is slated to meet with the FDA in mid-2025 to define the approval pathway and potentially initiate a U.S.-based clinical validation study in the second half of the year.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1